Literature DB >> 2158151

Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin.

P Hartl1, P Brücke, E Dienstl, H Vinazzer.   

Abstract

In a double blind randomized trial on 250 patients undergoing elective abdominal surgery the effect of Fragmin was compared with heparin. Patients over 40 years of age except appendectomy and herniotomy were included. The dose of heparin was 5,000 IU b.i.d. whilst Fragmin was given in a dose of 2,500 U once per day and the second injection was a placebo. Prophylaxis started 2 h preoperatively and was maintained for 7 days. The fibrinogen uptake test was used as a screening method for thrombosis which was confirmed by phlebography. 124 patients were in the heparin group and 126 in the Fragmin group. Comparability between groups was found in: age, sex, Broca index, amount and type of risk factors, type of surgery. Thromboembolism was found in 10 cases in each group. Blood transfusions on the postoperative days 1 to 6 were required in 2 Fragmin and in 12 heparin patients. The total amount of blood given during that time was 6 units in the Fragmin and 37 units in the heparin group. These differences were significant.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158151     DOI: 10.1016/0049-3848(90)90074-m

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.

Authors:  Adrienne Heerey; Sanjeev Suri
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 2.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 3.  Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.

Authors:  C J Dunn; B Jarvis
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

4.  Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy.

Authors:  A Lloyd; J A Aitken; U K Hoffmeyer; E J Kelso; E C Wakerly; N D Barber
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

Review 5.  Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  C J Dunn; E M Sorkin
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

6.  Low molecular weight heparin in prevention of perioperative thrombosis.

Authors:  A Leizorovicz; M C Haugh; F R Chapuis; M M Samama; J P Boissel
Journal:  BMJ       Date:  1992-10-17

Review 7.  Low molecular weight heparins. An objective overview.

Authors:  D Hoppensteadt; J M Walenga; J Fareed
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

8.  American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Authors:  David R Anderson; Gian Paolo Morgano; Carole Bennett; Francesco Dentali; Charles W Francis; David A Garcia; Susan R Kahn; Maryam Rahman; Anita Rajasekhar; Frederick B Rogers; Maureen A Smythe; Kari A O Tikkinen; Adolph J Yates; Tejan Baldeh; Sara Balduzzi; Jan L Brożek; Itziar Etxeandia- Ikobaltzeta; Herman Johal; Ignacio Neumann; Wojtek Wiercioch; Juan José Yepes-Nuñez; Holger J Schünemann; Philipp Dahm
Journal:  Blood Adv       Date:  2019-12-10

Review 9.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.